Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Triple FCDP (Saxagliptin/Dapagliflozin/Metformin XR) vs Individual Components
NCT03169959Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of saxagliptin, dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (12 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started May 2017; status: completed.
02
Drugs
saxagliptindapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03169959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169959.